172 related articles for article (PubMed ID: 3864526)
1. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
Arcamone F
Cancer Res; 1985 Dec; 45(12 Pt 1):5995-9. PubMed ID: 3864526
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
3. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
4. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
6. DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs.
Spadari S; Pedrali-Noy G; Focher F; Montecucco A; Bordoni T; Geroni C; Giuliani FC; Ventrella G; Arcamone F; Ciarrocchi G
Anticancer Res; 1986; 6(5):935-40. PubMed ID: 3026237
[TBL] [Abstract][Full Text] [Related]
7. Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxorubicin and mitoxantrone.
Zijlstra JG; Meijer C; Timmer-Bosscha H; Le TK; de Vries EG; Mulder NH
Eur J Respir Dis Suppl; 1987; 149():53-5. PubMed ID: 3034649
[No Abstract] [Full Text] [Related]
8. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
[TBL] [Abstract][Full Text] [Related]
9. [Models of preclinical studies of anthracyclines].
Fizames C
Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
[TBL] [Abstract][Full Text] [Related]
10. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
11. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells.
Capranico G; Soranzo C; Zunino F
Cancer Res; 1986 Nov; 46(11):5499-503. PubMed ID: 3463414
[TBL] [Abstract][Full Text] [Related]
12. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
13. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of chronic oral daily administration of idarubicin.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Rimondi G; Bearz A; Stocco F; Robieux I; Boiocchi M
Haematologica; 1997; 82(5 Suppl):1-3. PubMed ID: 9402745
[TBL] [Abstract][Full Text] [Related]
15. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
Capranico G; Riva A; Tinelli S; Dasdia T; Zunino F
Cancer Res; 1987 Jul; 47(14):3752-6. PubMed ID: 3474061
[TBL] [Abstract][Full Text] [Related]
16. [New anthracyclines in the treatment of solid tumors in the advanced stage].
Pannuti F; Martoni A; Lelli G; Camaggi CM; Strocchi E; Fruet F
G Ital Chemioter; 1985; 32(1):49-56. PubMed ID: 3868636
[No Abstract] [Full Text] [Related]
17. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.
Hu XF; Slater A; Rischin D; Kantharidis P; Parkin JD; Zalcberg J
Br J Cancer; 1999 Feb; 79(5-6):831-7. PubMed ID: 10070877
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
19. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
